Delonix's proprietary PathX platform integrates pathogen genome editing, strain optimization, and manufacturing know-how into an end-to-end bacterial engineering workflow for vaccine development.
Unlike conventional approaches that rely on antibiotic selection markers, PathX enables scarless genome editing and supports precise point mutations, gene deletions, gene insertions, and multiplex genome editing. The platform also incorporates advanced counter-selection strategies, diverse gene expression elements, and sophisticated protein display systems to enable efficient engineering of pathogenic bacteria.
PathX provides reusable genome-editing workflows across 16+ clinically important bacterial pathogens, supporting the rational design and development of next-generation bacterial vaccines.
Our Pathogen Editing Capabilities
- Pseudomonas aeruginosa
- Klebsiella pneumoniae
- Acinetobacter baumannii
- Salmonella typhimurium
- Helicobacter pylori
- Escherichia coli
- Enteropathogenic Escherichia coli
- Shigella flexneri
- Neisseria meningitidis
- Neisseria gonorrhoeae
- Bordetella pertussis
- Staphylococcus aureus
- Staphylococcus epidermidis
- Streptococcus pneumoniae
- Mycobacterium bovis
- Mycobacterium smegmatis
| Gram-Negative Bacteria | |
|---|---|
| Pseudomonas aeruginosa | Enteropathogenic Escherichia coli |
| Klebsiella pneumoniae | Shigella flexneri |
| Acinetobacter baumannii | Neisseria meningitidis |
| Salmonella typhimurium | Neisseria gonorrhoeae |
| Helicobacter pylori | Bordetella pertussis |
| Escherichia coli |
| Gram-Positive |
|---|
| Staphylococcus aureus |
| Staphylococcus epidermidis |
| Streptococcus pneumoniae |
| Mycobacterium bovis |
| Mycobacterium smegmatis |
OMV Plus is our proprietary genetically engineered OMV technology platform, which enables robust OMV vaccine candidate generation. Validated by the development of a potential BIC group B meningococcal vaccine
leverage 20 years+ pathogen genome editing and reverse vaccinology expertise for the rational design of next-generation OMV vaccine
successful track records in 100L manufacturing (yield 1M+ doses per run) with partner WuXi Vaccines; at least 5x cost reduction compared to existing products
end-to-end solution that enables IND application of co-development pipeline within 18 months from project initiation (after vaccine design confirmed)
adaptable genome editing to 16+ pathogens, enabling rapid generation of better “individualized” OMV vaccine candidates
- BioDVax (BioDesigned bacterial factory for subunit vaccine): BioDVax engineers polysaccharide toxin and other components of pathogens, aiming to improve subunit vaccine immunogenicity and optimize manufacturing process with higher yield and more consistent production.
- ProBVax (Programming bacterial cells for whole cell vaccine): ProBVax leverages rational design and novel bacterial immune checkpoint MOA to develop next generation live-attenuated vaccine, enabling fast optimization of safety and efficacy.